Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
+2.33M
-
Total reported value, excl. options
-
$907M
-
Value change
-
+$19.5M
-
Put/Call ratio
-
0.26
-
Number of buys
-
74
-
Number of sells
-
-66
-
Price
-
$8.63
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2016
193 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2016.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 124M outstanding shares and own 84.9% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.3M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (8.19M shares), VANGUARD GROUP INC (7.61M shares), BB BIOTECH AG (7.38M shares), First Eagle Investment Management, LLC (7.1M shares), FMR LLC (6.69M shares), BlackRock Fund Advisors (4.35M shares), STATE STREET CORP (3.58M shares), JPMORGAN CHASE & CO (3.08M shares), and BlackRock Institutional Trust Company, N.A. (2.85M shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.